Dupixent is filed at EMA as add-on maintenance treatment in certain adults and adolescents (12 years of age and older) with inadequately controlled moderate-to-severe asthma.-Sanofi.
The European Medicines Agency (EMA) has accepted for review an application for Dupixent (dupilumab) as an add-on maintenance treatment in certain adults and adolescents (12 years of age and older) with inadequately controlled moderate-to-severe asthma. Dupixent is a human monoclonal antibody specifically designed to inhibit signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13), two important signaling proteins (cytokines) that contribute to Type 2 inflammation in inadequately controlled moderate-to-severe asthma.
The application is supported by clinical data from 2,888 adults and adolescents who participated in three pivotal trials from the LIBERTY ASTHMA clinical development program. Detailed results from two of these trials, the Phase III QUEST and VENTURE trials, will be presented at the American Thoracic Society 2018 International Conference in May. In addition, the FDA is reviewing a supplemental Biologics License Application for Dupixent as an add-on maintenance treatment in certain adults and adolescents (12 years of age and older) with moderate-to-severe asthma, with a target action date of October 20, 2018.
Dupixent is currently approved in the European Union for use in adults with moderate-to-severe atopic dermatitis (eczema) who are candidates for systemic therapy. Dupixent is approved in the U.S. for the treatment of adults with moderate-to-severe atopic dermatitis that is not well controlled with prescription therapies used on the skin (topical), or when those therapies are not advisable. Dupixent is also approved for use in certain patients with moderate-to-severe atopic dermatitis in a number of other countries, including Canada, Japan and Australia. The potential use of Dupixent for the treatment of adults and adolescents (12 years of age and older) with inadequately controlled moderate-to-severe asthma is currently under regulatory review and the safety and efficacy for this use have not been fully evaluated by any regulatory authority.
The Respiratory Care Learning Zone contains essential information on Inhaled Therapies in Asthma and COPD and its Management. The Learning Zone also has an Educational Resources section which features slide kits, congress news and webinars and videos relevant to asthma and COPD.
Related news and insights
Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced that Health Canada has approved Ferriprox (deferiprone) for the treatment of iron overload in patients with sickle cell disease (SCD) or other anemias.
Zai Lab Limited and its partner Entasis Therapeutics Holdings Inc. announced topline results from the ATTACK trial, a global Phase III registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii.